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A tennis lesson: sharp practice in the
science behind the Sharapova case
Arduino Arduini,1 Victor A Zammit2
Maria Sharapova (and hundreds of other
elite athletes) took meldonium, a drug
developed at the time of the USSR for the
treatment of heart attack and stroke,
though it has never been approved for use
anywhere outside of the former Soviet
Union. Meldonium is an inhibitor of
γ-butyrobetaine hydroxylase, an enzyme
involved in the carnitine biosynthetic
pathway.1 Intake results in a reduction of
tissue carnitine content, including the
heart and skeletal muscles. Carnitine plays
a critical role in transferring long-chain
fatty acids across mitochondrial inner
membrane into the mitochondrial matrix,
to enable entry of the fatty acid moiety
into the oxidation pathway, to synthesise
ATP aerobically.2 In cases when intracellu-
lar carnitine availability is compromised,
such as in neonatal primary carnitine
deﬁciency,3 those affected experience
hypoglycaemia, fatigue, seizures and car-
diomyopathy.3 Carnitine-deﬁcient indivi-
duals are sensitive to prodrugs containing
the pivaloyl moiety, as pivalic acid is a
prodrug able to induce carnitine deﬁ-
ciency (like meldonium); this results in
lethal cardiac arrhythmias.4 Meldonium
administered orally at ‘recommended’
doses (500 mg, twice daily)5 would not
have such a drastic effect. However, even
a moderate reduction of muscle carnitine
content in healthy volunteers treated with
pivaloyl-conjugated antibiotics for 54 days
reduces work at maximal oxygen uptake
(VO2max), maximal heart rate,
6 reduced
interventricular septum thickness and left
ventricular mass.7 The oral administration
of meldonium to healthy volunteers
(500 mg, twice daily) for 4 weeks leads to
a signiﬁcant 18% reduction of plasma car-
nitine.5 Even though we are not aware of
the meldonium dosage prescribed to Ms
Sharapova, it is safe to assume that, in the
absence of oral carnitine supplementation,
her muscle carnitine content would have
been, at most, only modestly decreased,
and would have resulted in a minimal
impact on her muscle oxidative capacity,
as evidenced by her continued perform-
ance at the highest levels in her sport. The
medical team looking after Ms Sharapova
appears to have confounded the tangible
beneﬁcial effects of depressing acylcarni-
tine formation in ischaemic heart (which
may improve glucose use, eg, during
ischaemia–reperfusion) with the require-
ment of normal cardiac muscle for high
rates of carnitine-dependent fatty acid oxi-
dation. A recent study in rodents has
shown that even a moderate, silent
carnitine-deﬁcient phenotype may reveal
its fragility when subjected to strong
adrenergic stress.8 Therefore, unless mel-
donium has unidentiﬁed off-target
pharmacological effects, one has to be
thankful that it was not administered in
high enough doses so as to damage the
athletes who continued to take it.
Another aspect of meldonium pharma-
cology is the inhibition of carnitine acetyl-
transferase (CAT) activity,9 an enzyme that
reversibly transfers the acetyl moiety of
acetyl coenzyme A to carnitine in mito-
chondria and peroxisomes. Due to its cap-
acity to buffer mitochondrial acetyl
coenzyme A levels, CAT plays a promin-
ent role in intermediary metabolism and
muscle bioenergetics.2 As expected, in
rodent models, a lowered muscle CAT
activity results in muscle fatigue and exer-
cise intolerance.10 This would again
strongly argue against the use of meldo-
nium as a performance-enhancing drug,
particularly if such CAT-inhibitory activity
is combined with carnitine depletion.
The World Anti-Doping Agency (WADA)
may have decided to add meldonium to the
Prohibited List, not necessarily because of
any illusory performance-enhancing action
in healthy athletes, but because of the real
danger that it carries for the overenthusiastic
athlete who may overdose on it and lower
intracellular carnitine to pathological levels.
A comprehensive literature search of several
databases failed to unearth any cogent evi-
dence of the potential meldonium effect in
enhancing physical performance in healthy
subjects, with only one clinical trial con-
ducted on a small cohort of old (average
>60 year) patients with angina pectoris, to
evaluate exercise tolerance. On such
minimal ﬁndings is the dangerous extrapola-
tion to an assumed performance-enhancing
effect of meldonium in healthy elite athletes
based. It is not an overstatement to
emphasise that the understanding of metab-
olism is a postmodernist discipline in which
neither the inadequately trained scientists
(Metabolism is a Cinderella subject in most
universities) nor the editors of journals or
the clinicians who peruse their publications
know how to interpret the intricacies of
control in metabolism. This is an era in
which metabolic science is overrun by over-
emphasis on gross changes in gene expres-
sion, and too little on the reductionist
discipline of the study of the function of
proteins, their interactions, and their effects
on metabolic ﬂuxes. Athletes chasing the
shadows of marginal gains are the unwitting
victims. Hats off to WADA who may have
recognised that, even in the absence of any
performance-enhancing properties of mel-
donium, they should ban it for health
reasons. If anything, Ms Sharapova and
other ill-advised athletes may not have
attained their true athletic potential as a
result of having taken meldonium.
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